MARISSA HILL: Open Payments
NPI 1851013791 · NEW YORK, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$604 in 32 payments from 14 companies in 2025. Trend: 2023 $265 · 2024 $203 · 2025 $604
Food & beverage: $604
| Company | Payments | Amount |
|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $94 |
| AstraZeneca Pharmaceuticals LP | 6 | $88 |
| Otsuka America Pharmaceutical, Inc. | 3 | $73 |
| Novo Nordisk Inc | 4 | $61 |
| Corcept Therapeutics | 3 | $55 |
| Intra-Sana Laboratories | 1 | $50 |
| Abbott Laboratories | 3 | $46 |
| Medtronic, Inc. | 2 | $28 |
| Stryker Corporation | 1 | $22 |
| Sumitomo Pharma America, Inc. | 1 | $20 |
Products named: Kerendia, REXULTI, Korlym, RELTONE 200 MG, Wegovy, AIRSUPRA, INTELLIS ADAPTIVESTIM, Rybelsus.
Industry payments across NY — which companies pay providers there.
